ADMS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADMS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Adamas Pharmaceuticals's Cash Ratio for the quarter that ended in Sep. 2021 was 3.49.
Adamas Pharmaceuticals has a Cash Ratio of 3.49. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Adamas Pharmaceuticals's Cash Ratio or its related term are showing as below:
During the past 9 years, Adamas Pharmaceuticals's highest Cash Ratio was 24.14. The lowest was 1.64. And the median was 9.05.
The historical data trend for Adamas Pharmaceuticals's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adamas Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||||||
Cash Ratio | Get a 7-Day Free Trial | 11.66 | 10.44 | 8.69 | 4.92 | 2.39 |
Adamas Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | |
Cash Ratio | Get a 7-Day Free Trial | 2.94 | 2.39 | 4.28 | 4.19 | 3.49 |
For the Drug Manufacturers - Specialty & Generic subindustry, Adamas Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Adamas Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Adamas Pharmaceuticals's Cash Ratio falls into.
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Adamas Pharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2020 is calculated as:
Cash Ratio (A: Dec. 2020 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 83.365 | / | 34.867 | |
= | 2.39 |
Adamas Pharmaceuticals's Cash Ratio for the quarter that ended in Sep. 2021 is calculated as:
Cash Ratio (Q: Sep. 2021 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 83.098 | / | 23.843 | |
= | 3.49 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adamas Pharmaceuticals (NAS:ADMS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Vijay Shreedhar | officer: Chief Commercial Officer | C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608 |
Christopher B Prentiss | officer: Chief Financial Officer | 1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608 |
Anna Richo | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
David L Mahoney | director | SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014 |
Mardi Dier | director | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
William W. Ericson | director, 10 percent owner | 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404 |
John A Macphee | director | C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608 |
Ivan M Lieberburg | director | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Michael Bigham | director | 890 WINTER STREET, WALTHAM MA 02451 |
Martha J Demski | director | 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122 |
Neil F. Mcfarlane | officer: Chief Executive Officer | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Alfred G Merriweather | officer: Chief Financial Officer | |
Jennifer J Rhodes | officer: CBO, GC & Compliance Officer | C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608 |
Gregory T Went | director, officer: Chief Executive Officer | C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608 |
Rajiv Patni | officer: Chief Medical Officer | C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 10-19-2021
By Business Wire Business Wire • 10-08-2021
By PRNewswire PRNewswire • 10-16-2021
By Marketwired Marketwired • 10-12-2021
By Business Wire Business Wire • 10-11-2021
By Business Wire Business Wire • 09-16-2021
By Business Wire Business Wire • 08-02-2021
By Business Wire Business Wire • 07-09-2021
By Business Wire Business Wire • 08-09-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.